Intra-Cellular Therapies, Inc. financial data

Symbol
ITCI on Nasdaq
Industry
Pharmaceutical Preparations
Location
430 East 29 Th Street, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Oneida Resources Corp. (to 8/29/2013)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 636 % -27.2%
Quick Ratio 17.3 % -51.1%
Debt-to-equity 19.7 % +27.8%
Return On Equity -11.5 % +59.9%
Return On Assets -9.6 % +61.3%
Operating Margin -105 % +69.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 106M shares +9.97%
Common Stock, Shares, Outstanding 106M shares +9.93%
Entity Public Float 6B USD
Common Stock, Value, Issued 11K USD +10%
Weighted Average Number of Shares Outstanding, Basic 104M shares +8.1%
Weighted Average Number of Shares Outstanding, Diluted 104M shares +8.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 250M USD +199%
Revenue from Contract with Customer, Excluding Assessed Tax 565M USD +54.3%
Research and Development Expense 191M USD +23.5%
General and Administrative Expense 445M USD +16.1%
Operating Income (Loss) -112M USD +43.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -83.4M USD +54.7%
Income Tax Expense (Benefit) 907K USD +521%
Net Income (Loss) Attributable to Parent -84.3M USD +54.3%
Earnings Per Share, Basic -0.87 USD/shares +54.9%
Earnings Per Share, Diluted -0.87 USD/shares +54.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 693M USD +387%
Accounts Receivable, after Allowance for Credit Loss, Current 146M USD +51.8%
Inventory, Net 20.1M USD -52.1%
Assets, Current 1.26B USD +81.1%
Property, Plant and Equipment, Net 1.45M USD -12.7%
Operating Lease, Right-of-Use Asset 14.5M USD +5.22%
Other Assets, Noncurrent 7.74M USD +8899%
Assets 1.32B USD +85%
Accounts Payable, Current 17.5M USD +127%
Liabilities, Current 162M USD +75.7%
Operating Lease, Liability, Noncurrent 14.1M USD -2.18%
Liabilities 176M USD +65.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -668K USD +70.5%
Retained Earnings (Accumulated Deficit) -1.65B USD -5.39%
Stockholders' Equity Attributable to Parent 1.14B USD +88.5%
Liabilities and Equity 1.32B USD +85%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.1M USD +43.2%
Net Cash Provided by (Used in) Financing Activities 9.99M USD +174%
Net Cash Provided by (Used in) Investing Activities 16.2M USD
Common Stock, Shares Authorized 175M shares 0%
Common Stock, Shares, Issued 106M shares +9.93%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.95M USD +89.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 695M USD +383%
Deferred Tax Assets, Valuation Allowance 271M USD +22.8%
Operating Lease, Liability 18.3M USD +1.66%
Depreciation 132K USD -1.49%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -82.7M USD +54.5%
Lessee, Operating Lease, Liability, to be Paid 22.7M USD -3.04%
Property, Plant and Equipment, Gross 7.14M USD +12.2%
Operating Lease, Liability, Current 4.17M USD +17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.51M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.44M USD +17%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.46M USD -18.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.57M USD +15.1%
Deferred Tax Assets, Operating Loss Carryforwards 139M USD -17.7%
Unrecognized Tax Benefits 2.5M USD +47.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.71M USD +17%